This review concluded that, despite greater donor-recipient human leukocyte antigen disparity, unrelated donor cord blood transplantation has consistently equivalent survival outcomes in both children and adults with malignant and nonmalignant disorders compared with unrelated donor bone marrow transplantation. However, the suggestion of significant statistical and possibly clinical variability suggests that the authors' conclusions may not be reliable.
Assessment of study quality
The consistency, accuracy and comparability of treatment group characteristics were assessed; no further details were reported. The authors did not state how many reviewers performed the validity assessment, or how any disagreements were resolved.
Data extraction
Three reviewers independently extracted the data using a standardised data extraction form. Any disagreements were resolved through consultation with a statistician. Study authors were contacted for additional or missing data. Data for neutrophil and platelet engraftment, TRM, relapse, GVHD and overall or event-free survival were extracted.
Relative risks (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous data (e.g. incidence of GVHD) and hazard ratios (HRs) with 95% CIs for time-to-event data (e.g. overall mortality, disease-free survival, TRM and relapse occurring over time). If HRs were not available in the original paper they were estimated (where possible) from Kaplan-Meier curves.
Methods of synthesis
How were the studies combined? The studies were grouped by outcome and pooled RRs or HRs, with 95% CIs, were calculated using either a fixedeffect analysis or, in the event of significant statistical heterogeneity, a random-effects analysis. Only TRM in children appears to have been pooled using a fixed-effect analysis; the other outcomes were pooled using a random-effects analysis.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the I-squared statistic. Some clinical differences between the studies were evident from the tables and text.
Results of the review
Six studies were included in the review; three included children (n=477) and three included adults (n=1,312).
In terms of study quality, randomisation and blinding were not possible. All of the studies had minor differences in the patient characteristics of the study groups, but these were usually not significant.
Children.
Two studies showed a lower probability of white cell engraftment for UCBT at 45 days (HR 0.92, 95% CI: 0.79, 1.08; 1 study) and 60 days (HR 0.84, 95% CI: 0.76, 0.93; 1 study). Time to platelet independence or engraftment was similar for both UCBT and UBMT (HR 1.06, 95% CI: 0.97, 1.15, p=1.09; 2 studies). The risk of having early (day 100) TRM was lower with UBMT (HR 2.08, 95% CI: 1.37, 3.16, p=0.0006; 2 studies). The risk of relapse was significantly lower in patients with UCBT (HR 1.96, 95% CI: 1.12, 3.43; 1 study). There were no significant differences in overall survival at 2 years (HR 0.76, 95% CI: 0.31, 1.87, p=0.55; 2 studies) or 3 years (HR 1.95, 95% CI: 0.44, 2.54, p=0.91; 1 study). UBMT was associated with improved disease-free survival (HR 0.60, 95% CI: 0.45, 0.81; 1 study). There were no significant differences between UCBT and UBMT in GVHD grade II-IV (HR 0.96, 95% CI: 0.44, 2.09, p=0.92; 3 studies) and grade III-IV (HR 1.46, 95% CI: 0.42, 5.03, p=0.55; 3 studies); however, there was evidence of significant heterogeneity between the studies. When only chronic GVHD was assessed, rates were significantly lower with UCBT (HR 0.26, 95% CI: 0.12, 0.57, p=0.0007; 2 studies).
Adults.
The risk of experiencing a relapse (HR 0.86, 95% CI: 0.62, 1.19, p=0.36; 3 studies) and early TRM (HR 1.04, 95% CI: 0.52, 2.08, p=0.91; 3 studies) was the same in the UCBT and UBMT groups. Studies assessing overall survival could not be pooled, but 2 studies showed a significant difference in favour of UBMT. No significant differences were observed between UCBT and UBMT for disease-free survival (HR 1.56, 95% CI: 0.76, 3.17, p=0.23; 3 studies); however, there was evidence of significant heterogeneity between the studies. UBMT was shown to be consistently better than UCBT
